These regional markets accounting for a combined market size of US$225.9 Million in the year 2020 will reach a projected size of US$513 Million by the close of the analysis period. In the global Hybridization-based segment, USA, Canada, Japan, China and Europe will drive the 12.6% CAGR estimated for this segment. Cancer testing constitutes a common application for ISH. ISH is used for identifying bacterial infections. ISH or In Situ-Hybridization is another important molecular diagnostic technology. Hybridization-based Segment to Reach $612.3 Million by 2026 Within Europe, Germany is forecast to grow at approximately 13.6% CAGR while Rest of European market (as defined in the study) will reach US$619.5 Million by the end of the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.8% and 13.5% respectively over the analysis period. China, the world`s second largest economy, is forecast to reach an estimated market size of US$558.7 Million in the year 2026 trailing a CAGR of 17.6% through the analysis period. The country currently accounts for a 39.71% share in the global market. is estimated at US$1.1 Billion in the year 2021. The Point of Care (POC) Molecular Diagnostics market in the U.S. Market is Estimated at $1.1 Billion in 2021, While China is Forecast to Reach $558.7 Million by 2026 Also, technological developments, over the years, have led to the development of sequencing products which need very less time for evaluating RNA, DNA and other cellular functions.
Reduced costs would be the major factor that would make the technologies more attractive. The emergence of Next-Generation Sequencing (NGS) technology contributes to the development of innovative, yet cost-effective molecular diagnostic tests. Other factors driving growth in the technology segment include growing demand for personalized medicine, pharmacogenomics and inventive diagnostic tests. PCR technologies enable detection of diseases in early stages, a major factor that is contributing for market`s growth. This segment currently accounts for a 19.5% share of the global Point of Care (POC) Molecular Diagnostics market. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Genetic Sequencing-Based segment is readjusted to a revised 11.4% CAGR for the next 7-year period. PCR-based, one of the segments analyzed in the report, is projected to grow at a 15.5% CAGR to reach US$3.6 Billion by the end of the analysis period. Introduction of new diagnostics tests, primarily in the infectious disease application area is likely to keep the momentum going for molecular diagnostics over the forthcoming years.Īmid the COVID-19 crisis, the global market for Point of Care (POC) Molecular Diagnostics estimated at US$2.2 Billion in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2026, growing at a CAGR of 14.4% over the analysis period.
The growing application of healthcare information technology for providing accurate diagnostics constitutes yet another factor supporting growth for molecular diagnostics market. Increasing use of molecular diagnostics for home healthcare is another important growth driving factor for the market. Reimbursement reformations are also to an extent contributing towards fueling market growth. Other important factors to propel growth include growing awareness and acceptance of advanced therapeutic and diagnostic choices such as personalized medicine biomarkers development and advancement in proteomics and molecular techniques. Increasing prevalence of various cancers and infectious disease types constitutes the major factor to drive growth for the market for the market in the coming years. Growth in the global market is being driven by faster development and commercialization of novel and more advanced technologies, and also the faster shift of such advanced tests from labs to point of care (POC) settings. Molecular diagnostic technology is currently being used for performing oncology, coagulation, antigen typing, human leukocyte, infectious diseases, and genetic disease screening. Point-Of-Care (POC) molecular diagnostics refer to tests that are performed at nearby patient locations such as clinics, hospitals, and ambulances. Global Point of Care (POC) Molecular Diagnostics Market to Reach US$5.2 Billion by the Year 2026 Access to our digital archives and MarketGlass Research Platform Online interactive peer-to-peer collaborative bespoke updates
22, 2022 (GLOBE NEWSWIRE) - announces the release of the report "Global Point of Care (POC) Molecular Diagnostics Industry".
0 kommentar(er)
